Literature DB >> 24173295

Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment.

Elsa Gilbert1, Chantal Mérette, Valérie Jomphe, Claudia Emond, Nancie Rouleau, Roch-Hugo Bouchard, Marc-André Roy, Thomas Paccalet, Michel Maziade.   

Abstract

Cognitive impairments are central to schizophrenia, but their clinical utility for tagging heterogeneity in lifetime outcome and response to treatment is not conclusive. By exploiting four cognitive domains consistently showing large deficits in studies, we tested whether cluster analysis would define separate subsets of patients and then whether the disease heterogeneity marked by these clusters would be related to lifetime outcome and response to treatment. A total of 112 schizophrenia patients completed a neuropsychological evaluation. The PANSS, GAF-S and GAF-F were rated at the onset and endpoint of the illness trajectory. A blind judgment of the lifetime response to treatment was made. The first cluster presented near-normal cognitive performance. Two other clusters of severely impaired patients were identified: one generally impaired in the four cognitive domains and another selectively impaired in visual episodic memory and processing speed, each relating to a different lifetime evolution of disease and treatment response. Although the two impaired clusters were clinically indistinguishable in symptom severity and functioning at disease onset, patients with selective cognitive impairments demonstrated better improvement at outcome, whereas the generally impaired patients were more likely to be treatment refractory. The findings have implications for the management of patients and for clinical trials since particular combinations of cognitive deficits in patients would influence their treatment response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24173295      PMCID: PMC5025284          DOI: 10.1007/s00406-013-0463-7

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  66 in total

1.  Cognitive factor structure and invariance in people with schizophrenia, their unaffected siblings, and controls.

Authors:  Dwight Dickinson; Terry E Goldberg; James M Gold; Brita Elvevåg; Daniel R Weinberger
Journal:  Schizophr Bull       Date:  2010-03-29       Impact factor: 9.306

2.  An investigation of 3 neurocognitive subtypes in schizophrenia.

Authors:  Narmeen Ammari; R Walter Heinrichs; Ashley A Miles
Journal:  Schizophr Res       Date:  2010-06-20       Impact factor: 4.939

Review 3.  Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.

Authors:  Diana O Perkins; Hongbin Gu; Kalina Boteva; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

4.  The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance.

Authors:  J Endicott; R L Spitzer; J L Fleiss; J Cohen
Journal:  Arch Gen Psychiatry       Date:  1976-06

5.  Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort.

Authors:  Mary Cannon; Avshalom Caspi; Terrie E Moffitt; HonaLee Harrington; Alan Taylor; Robin M Murray; Richie Poulton
Journal:  Arch Gen Psychiatry       Date:  2002-05

6.  Neuropsychological profiles delineate distinct profiles of schizophrenia, an interaction between memory and executive function, and uneven distribution of clinical subtypes.

Authors:  S Kristian Hill; J Daniel Ragland; Ruben C Gur; Raquel E Gur
Journal:  J Clin Exp Neuropsychol       Date:  2002-09       Impact factor: 2.475

7.  Stability and course of neuropsychological deficits in schizophrenia.

Authors:  R K Heaton; J A Gladsjo; B W Palmer; J Kuck; T D Marcotte; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  2001-01

Review 8.  Identification of separable cognitive factors in schizophrenia.

Authors:  Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

9.  Neuropsychological correlates of negative, disorganized and psychotic symptoms in schizophrenia.

Authors:  M R Basso; H A Nasrallah; S C Olson; R A Bornstein
Journal:  Schizophr Res       Date:  1998-05-25       Impact factor: 4.939

10.  Cognitive function in childhood and early adulthood and hospital admission for schizophrenia and bipolar disorders in Danish men born in 1953.

Authors:  Merete Osler; Debbie A Lawlor; Merete Nordentoft
Journal:  Schizophr Res       Date:  2007-03-06       Impact factor: 4.939

View more
  16 in total

Review 1.  Annual Research Review: Discovery science strategies in studies of the pathophysiology of child and adolescent psychiatric disorders--promises and limitations.

Authors:  Yihong Zhao; F Xavier Castellanos
Journal:  J Child Psychol Psychiatry       Date:  2016-01-06       Impact factor: 8.982

2.  Brain Structure in Neuropsychologically Defined Subgroups of Schizophrenia and Psychotic Bipolar Disorder.

Authors:  Neil D Woodward; Stephan Heckers
Journal:  Schizophr Bull       Date:  2015-04-22       Impact factor: 9.306

3.  Childhood abuse and neglect may induce deficits in cognitive precursors of psychosis in high-risk children.

Authors:  Nicolas Berthelot; Thomas Paccalet; Elsa Gilbert; Isabel Moreau; Chantal Mérette; Nathalie Gingras; Nancie Rouleau; Michel Maziade
Journal:  J Psychiatry Neurosci       Date:  2015-09       Impact factor: 6.186

4.  The neuropathology of schizophrenia: new insights from postmortem studies.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-06       Impact factor: 5.270

5.  Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.

Authors:  T Scott Stroup; Natalie A Bareis; Robert A Rosenheck; Marvin S Swartz; Joseph P McEvoy
Journal:  J Clin Psychiatry       Date:  2018-11-27       Impact factor: 4.384

Review 6.  Theoretical Modeling of Cognitive Dysfunction in Schizophrenia by Means of Errors and Corresponding Brain Networks.

Authors:  Yuliya Zaytseva; Iveta Fajnerová; Boris Dvořáček; Eva Bourama; Ilektra Stamou; Kateřina Šulcová; Jiří Motýl; Jiří Horáček; Mabel Rodriguez; Filip Španiel
Journal:  Front Psychol       Date:  2018-07-03

7.  Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment.

Authors:  Diego Scheggia; Rosa Mastrogiacomo; Maddalena Mereu; Sara Sannino; Richard E Straub; Marco Armando; Francesca Managò; Simone Guadagna; Fabrizio Piras; Fengyu Zhang; Joel E Kleinman; Thomas M Hyde; Sanne S Kaalund; Maria Pontillo; Genny Orso; Carlo Caltagirone; Emiliana Borrelli; Maria A De Luca; Stefano Vicari; Daniel R Weinberger; Gianfranco Spalletta; Francesco Papaleo
Journal:  Nat Commun       Date:  2018-06-11       Impact factor: 14.919

Review 8.  A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits.

Authors:  Tesfa Dejenie Habtewold; Lyan H Rodijk; Edith J Liemburg; Grigory Sidorenkov; H Marike Boezen; Richard Bruggeman; Behrooz Z Alizadeh
Journal:  Transl Psychiatry       Date:  2020-07-21       Impact factor: 6.222

9.  Long-term cognitive trajectories and heterogeneity in patients with schizophrenia and their unaffected siblings.

Authors:  Md A Islam; T D Habtewold; F D van Es; P J Quee; E R van den Heuvel; B Z Alizadeh; R Bruggeman
Journal:  Acta Psychiatr Scand       Date:  2018-09-21       Impact factor: 6.392

10.  Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ÆSOP-10 study.

Authors:  Eugenia Kravariti; Arsime Demjaha; Jolanta Zanelli; Fowzia Ibrahim; Catherine Wise; James H MacCabe; Abraham Reichenberg; Izabela Pilecka; Kevin Morgan; Paul Fearon; Craig Morgan; Gillian A Doody; Kim Donoghue; Peter B Jones; Anil Şafak Kaçar; Paola Dazzan; Julia Lappin; Robin M Murray
Journal:  Psychol Med       Date:  2018-10-23       Impact factor: 10.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.